Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 1/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14049427 | 0.94 | ADRB3 (0.51) | ADRB3ADRA2BADRA2CCYP3A4CTSB | |
| SCHEMBL8286044 | 0.89 | ADRB3 (0.45) | ADRB3ADRA2BADRA2CCYP3A4CTSB | |
| SCHEMBL14031195 | 0.85 | ADRB3 (0.52) | ADRB3ADRA2BADRA2CCYP3A4CTSB | |
| SCHEMBL13915585 | 0.85 | ADRB3 (0.52) | ADRB3ADRA2BADRA2CCYP3A4CTSB | |
| SCHEMBL14049430 | 0.83 | ADRB3 (0.47) | ADRB3ADRA2BADRA2CCYP3A4CTSB | |
| SCHEMBL14049482 | 0.81 | ADRB3 (0.46) | ADRB3ADRA2BADRA2CCYP3A4CTSB | |
| SCHEMBL13927459 | 0.80 | ADRB3 (0.48) | ADRB3ADRA2BADRA2CCYP3A4CTSB | |
| SCHEMBL14049098 | 0.80 | ADRB3 (0.39) | ADRB3ADRA2BADRA2CCYP3A4CTSB | |
| SCHEMBL10060874 | 0.79 | ADRB3 (0.63) | ADRB3ADRA2BADRA2CCYP3A4CTSB | |
| SCHEMBL3809694 | 0.79 | ADRB3 (0.49) | ADRB3ADRA2BADRA2CCYP3A4CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005051980-A1 | DEPEPTIDIZED INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | SCHERING CORPORATION (US) | 2005-06-09 | — | — | WO | disclosed |